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Background. There was a 6-month shortage of antiretrovirals (cART) in Kenya. Methods. We assessed morbidity, mortality, and
loss to follow-up (LTFU) in this retrospective analysis of adults who were enrolled during the six-month period with restricted
cART (cap) or the six months prior (pre-cap) and eligible for cART at enrollment by the pre-cap standard. Cox models were used
to adjust for potential confounders. Results. 9009 adults were eligible for analysis: 4,714 pre-cap and 4,295 during the cap. Median
numberofdays fromenrollment tocARTinitiation was 42pre-cap and 56 forthe cap (P<0.001). Afteradjustment, individualsin
the cap were at higher risk of mortality (HR = 1.21; 95% CI : 1.06–1.39) and LTFU (HR = 1.12; 95% CI : 1.04–1.22). There was no
diﬀerence between the groups in their risk of developing a new AIDS-deﬁning illness (HR = 0.92 95% CI 0.82–1.03). Conclusions.
Rationing of cART, even for a relatively short period of six months, led to clinically adverse outcomes.
1.Introduction
Since the beginning of the HIV pandemic, almost 60 million
people have been infected with HIV and 25 million have
died from HIV-associated illnesses [1]. Sub-Saharan Africa
is the region most aﬀected by the pandemic and is home to
68% of all people living with HIV worldwide [1]. Since 2002,
the international drive to scale up antiretroviral treatment
has gained tremendous momentum [2], and by the close
of 2009, an estimated 5.2 million persons were receiving
combination antiretroviral treatment (cART). While this
represents important progress, this still is only about 35% of
the people who are estimated in need of treatment according
to current standards of care [1].
HIV/AIDS has largely been transformed into a man-
ageable, chronic disease for those with access to cART
[3]. The clinical beneﬁts of cART for individuals living in
resource-poor settings, including slow disease progression
and reduced mortality, have been documented in multiple
studies [4–6]. More speciﬁcally, recent data from Uganda
demonstrated that morbidity in HIV-infected individuals
decreased after the introduction of antiretroviral therapy
(ART); the decline became more apparent with increasing
duration on ART [7]. Nonetheless, questions remain about
the optimal time to begin treatment [8, 9].
Recent observational data from North America show
that the risk of death increased by 69% when initiation of
therapy is delayed until after the CD4 count drops below2 AIDS Research and Treatment
350cells/µL[ 8]. The nadir CD4 count is predictive of the
beneﬁt that will be gained from cART initiation [8, 10].
Prior to November 2009, guidelines for low-income settings
recommended initiating treatment when a patient’s CD4
count dropped below 200cells/µL[ 11]. The guidelines were
revised in November 2009 and now recommend initiation of
treatment earlier in the course of the disease, when the CD4
cell count falls below 350cells/µL[ 12]. Unfortunately, many
clinics and treatment providers are already overwhelmed
with the number patients presenting for treatment [13]. The
capacity of the infrastructure to manage HIV as a chronic
illness is stretched, and though the guidelines for cART
initiation have been expanded, the capacity of clinics in
resource-constrained settings to meet the increased demand
is not clear [14]. Furthermore, international commitments
to continued funding and expansion of HIV treatment
programs are waning in the face of global ﬁnancial con-
straints [15, 16]. Rationing and waitlisting for treatment
initiationmaycontinuetobearealityformanyantiretroviral
treatment programs given these circumstances. The impact
of rationing treatment on patient clinical outcomes is not
well described.
From March 12, 2007 through August 31, 2007, Kenya
experienced a shortage of antiretroviral medications.
The United States Agency for International Development
(USAID) funded Academic Model Providing Access to
Healthcare (AMPATH) was asked by the Government of
Kenya to limit new cART initiations. The program agreed to
limit new cART starts to patients with CD4 < 100cells/µL,
eﬀectively “capping” new cART initiations for a period
of 6 months. The primary objective of this analysis was
to evaluate the impact of this restriction on morbidity,
mortality, and loss to follow-up among HIV-infected
patients who were eligible for cART. Our secondary objective
was to determine factors associated with actually receiving
cART among this population.
2. Methods
2.1. Study Design. This retrospective observational study
was approved by the Indiana University School of Medicine
Institutional Review Board and the Moi University Institu-
tional Research and Ethics Committee. Informed consent
was waived as a part of a general approval for conducting
retrospective analyses with de-identiﬁed data collected as a
part of routine care.
2.2. Study Setting. AMPATH, headquartered in Eldoret,
Kenya, was established in 2001 as a partnership between
Indiana University School of Medicine, Moi University
School of Medicine, and the Moi Teaching and Referral
Hospital. In 2004, AMPATH received funding from the
United States Presidential Emergency Plan for AIDS Relief
(PEPFAR) to create the USAID-AMPATH Partnership. The
original goal of the program was to establish an HIV care
network to serve the needs of patients in western Kenya. To
date,theprogramhasenrolledmorethan135,000patientsin
25 Ministry of Health facilities and numerous satellite clinics
around western Kenya. All HIV and tuberculosis-related care
and treatment are provided without cost to patients through
USAID-AMPATH and the Kenyan Department of Leprosy,
TB, and Lung Disease.
2.3. Study Population. The study population was limited
to patients who were not pregnant, aged 14 or older at
enrollment, and who were eligible for cART at enrollment
according to the pre-cap standard. Speciﬁcally, patients were
eligible for cART if they had (1) CD4 < 200cells/µLo r( 2 )
WHO stage IV illness or (3) WHO stage III AND CD4 <
350cells/µL. These criteria are consistent with the 2006 HIV
treatment guidelines from the World Health Organization
[17]. Pregnant women were excluded from the analysis
because they were exempted from the cap criteria (i.e., they
continued to be initiated on cART as usual). There were two
populations of eligible patients for this analysis: those who
enrolled during the six months prior to the restricted cART
period (September 1, 2006–March 11, 2007, called the “pre-
cap” period) and those who enrolled during the restricted
cART period (March 12–August 31, 2007, called the “cap”
period).
2.4. Data Collection and Management. Clinicians completed
standardized forms capturing demographic, clinical, and
pharmacologic information at each patient visit. These data
are then hand-entered into the AMPATH Medical Record
System (AMRS), a secure computerized database designed
for clinical management, with data entry validated by
random review of 10% of the forms entered [18, 19]. At
the time of registration, patients are provided with a unique
identifyingnumber.Forthisstudy,alldatawerede-identiﬁed
before analysis.
2.5. Outcomes and Explanatory Variables. The primary out-
comes for this analysis were morbidity, mortality (from
all causes) and loss to follow-up (LTFU). Morbidity is
deﬁned as a new WHO Stage III or IV illness 60 days after
enrollment to ensure that disease prevalent at enrolment
was not accidentally counted as an incident infection due
to delayed provider ascertainment. LTFU is deﬁned as being
absent from clinic for at least three months if on cART at
the last visit and with no indication that the patient had
died, or if not on cART at last visit, absent from clinic
for at least six months, with no indication that the patient
had died. AMPATH has a Standard Operating Procedure
for reporting deaths, which includes a standardized death
reporting form that is used for documentation of deaths by
all clinic personnel. AMPATH also has an active peer-led
outreach program which assists with death ascertainment.
Outreach workers complete locator information for all new
and returning patients in the clinical care program. The
locator card includes contact information and a map to the
patient’s residence and is used to ﬁnd the patient in the event
of a missed appointment. The AMPATH Medical Record
System (AMRS) produces a daily list of patients scheduled
for appointments and patients that miss their appointment
are listed for outreach based on a three-tier triage algorithm.AIDS Research and Treatment 3
Adult patients on CART for less than three months are
given priority. Outreach eﬀorts for these patients are to
commence within 24 hours of a missed appointment with
a goal of locating the patient within seven days. For patients
receiving CART for over three months, outreach is activated
within seven days after a missed appointment. Individuals
who do not receive CART are given 28 days from the
missed appointment prior to initiation of outreach activities.
However,thereisundoubtedlyunderascertainmentofdeaths
among patients LTFU—a recent evaluation of patients LTFU
found that 20% of patients LTFU were in fact deceased.
Independent variables were both sociodemographic and
clinical. We hypothesized that the following variables were
actual or potential confounders of the relationship between
the cap and death or LTFU and so were included in the
analyses: age (continuous), sex (male/female), WHO stage
(I, II, III, IV) and CD4 count (continuous) at enrollment,
use of Cotrimoxazole or Dapsone at enrollment, whether
the patient received TB treatment at enrolment, whether the
patient was attending an urban or a rural clinic, and the time
required for the patient to travel to clinic (<30 minutes, 30–
60 minutes, 1-2 hours, >2h o u r s ) .
2.6. Statistical Methods. Enrollment cohort characteristics of
t h e“ p r e - c a p ”g r o u pa n d“ c a p ”g r o u pw e r ec o m p a r e du s i n g
Fisher’s Exact test for categorical variables and Kruskal-
Wallis test for continuous variables. The Kaplan-Meier
method was used to estimate the survival functions of time
to morbidity, loss to follow-up and mortality. Time zero was
thedate ofenrollmentfortheloss to follow-upandmortality
analyses and 60 days after enrollment in the morbidity
model. The event date of loss to follow-up was the date of the
last clinic visit recorded in the database. Data on individuals
known to have died within 3 months of their last clinic visit
(if the patients were on cART, or 6 months if not on cART)
were censored at the date of their last visit in the LTFU
model. The patients on cART who are known to have died
more than 3 months after their last clinic visit (or more than
6 months if not on cART) were treated as LTFU at the date of
their last visit. Data for those who were still alive and not lost
to follow-up by the administrative closure of the database
were censored at the date of the last clinic visit. Survival
distributions were compared using the Wilcoxon Log Rank
test.
Cox Proportional Hazard models were used to calculate
adjusted hazard ratios with 95% conﬁdence intervals in
individual predictive models for the primary outcomes
(adjusting for the covariates described previously). In sec-
ondary analysis we explored the factors associated with
cART initiation using Cox models. Statistical signiﬁcance in
the Cox model was assessed by the Wald test. Variables, if
statistically signiﬁcant at an alpha of 0.05 in the univariate
model or, if believed to be potential confounders, were
entered into the ﬁnal model. All covariates in the tables were
adjusted for in the multivariate models.
All statistical analyses were performed using R software
(version 2.13.1; Vienna, Austria) and SAS (version 9.2; SAS
Institute, Cary, NC).
3. Results
3.1. Participants. There were 9,009 adults eligible for analy-
sis. Among whom, 60.2% were women, with a median age of
37.0 (interquartile range, IQR 30.9, 44.1). The median CD4
count at enrollment was 96 (IQR: 40, 162)cells/µL. Of the
9,009, 4,714 individuals were enrolled in the pre-cap period
and 4,295 were enrolled during the cap period. Patients were
followed for a median of 559 days (700 days in the pre-
cap group and 512 for the cap group). This diﬀerence is to
be expected since the pre-cap group were enrolled in the 6
months prior to the start of the cap period and thus had a
longer potential follow-up period.
The clinical and sociodemographic characteristics of
both groups are summarized in Table 1. Median CD4 count
at enrolment was similar between the two groups (99 versus
94). The groups were well balanced on all enrollment
characteristics except for use of Cotrimoxazole or Dapsone
prophylaxis (81.7% in the pre-cap group versus 76.4% in the
cap group, P<0.001).
3.2. Time to cART Initiation. There were 3,684 (78.2%)
individuals who initiated cART in the pre-cap group and
3,126 (72.8%) in the cap cohort (P<0.001). The median
number of days from enrollment to cART initiation was
50 days for the pre-cap cohort and 70 days for the cap
cohort (P<0.001). Factors associated with receiving cART
are summarized in Table 2. Individuals were more likely
to receive cART if they were receiving Cotrimoxazole or
Dapsone (P<0.001), if they were male (P<0.001), if they
wereWHOStageII,III,orIV(comparedtostageI),orifthey
attended an urban clinic (P = 0.030). Patients were less likely
to receive cART if they were enrolled during the cap period
(P<0.001), and if they were receiving TB treatment (P<
0.001). For each one cell increase in CD4 count there was
a 0.5% reduction in the likelihood of getting cART (Hazard
Ratio, HR: 0.995, 95% conﬁdence interval, CI: 0.995-0.996).
3.3. Morbidity. There were 1,358 new AIDS deﬁning events
during the follow-up period including 573 among the cap
group and 785 among the pre-cap group. After adjustment
for potential confounders, there was no eﬀect of the cap on
theriskofdevelopinganewWHOStageIIIorIVillness(HR:
0.92; 95% CI: 0.82, 1.03) (Figure 1(a), Table 3).
3.4. Mortality. There were 1030 deaths during the follow-up
period, including 538 among the cap group and 492 among
the pre-cap group. Among patients who died, the median
number of days to death in the cap group was 94 (IQR: 46,
201)comparedtothepre-capgroupwhichwas111(44,244).
Among the 492 deaths in the pre-cap group, 191 (38.8%)
diedbeforestartingcART,whileforthecapgroup,261outof
538 deaths (48.5%) were before cART initiation (P = 0.002).
The 1-year survival rate in the pre-cap group was 89.5%
(95%CI:88.5%,90.4%),comparedto85.6%(84.4%,86.8%)
in the cap group (Figure 1(b)). After adjusting for covariates,
the cap group had a signiﬁcantly higher risk of mortality4 AIDS Research and Treatment
Table 1: Enrollment sociodemographics and clinic characteristics of the comparison groups.
Variable Pre-cap group (n = 4714), n (%) Cap group (n = 4295), n (%) P value
Sex
Male 1849 (39.2) 1741 (40.5)
0.212 Female 2865 (60.8) 2554 (59.5)
Missing 0 (0) 0 (0)
Agea
Median 37.0 36.9
0.255 IQR 31.0–44.1 30.6–44.0
Missing 0 (0) 0 (0)
Clinic locationa
Urban 2315 (49.1) 2176 (50.7)
0.146 Rural 2399 (50.9) 2119 (49.3)
Missing 0 (0) 0 (0)
Travel time to clinica
<30 minutes 1093 (23.4) 962 (23.1)
0.100
30–60 minutes 1467 (31.5) 1400 (33.6)
1-2 hours 1266 (27.2) 1127 (27.0)
>2 hours 836 (17.9) 683 (16.4)
Missing 52 (1.1) 123 (2.9)
WHO clinical stagea
I 637 (15.1) 533 (14.5)
0.780
II 839 (19.8) 754 (20.6)
III 2278 (53.9) 1977 (54.0)
IV 476 (11.3) 400 (10.9)
Missing 484 (10.3) 631 (14.7)
CD4a
Median 99.0 94.0
0.081 IQR 41.0–163 38.0–161
Missing 59 (1.3) 49 (1.1)
Use of Cotrimoxazole or Dapsone
Yes 3851 (81.7) 3282 (76.4)
<0.001 No 863 (18.3) 1013 (23.6)
Missing 0 (0) 0 (0)
TB treatmenta
Yes 1180 (25.0) 1121 (26.1)
0.246 No 3534 (75.0) 3174 (73.9)
Missing 0 (0) 0 (0)
aAt Enrollment.
(HR = 1.21; 95% CI: 1.06, 1.39) compared to the pre-cap
group (Table 3).
3.5. Loss to Follow-Up. There were 3,537 patients lost to
follow-up, including 1,665 in the cap group and 1,872 in the
pre-cap group. The adjusted relative risk of becoming loss
to follow-up was 1.12 (1.04, 1.22) times greater for those
patients enrolled during the cap period versus the pre-cap
period (Figure 1(c), Table 3).
3.6. Sub-Analysis for Pneumocystis Prophylaxis. The patients
in the cap group were somewhat less likely to receive
Cotrimoxazole or Dapsone compared to the pre-cap group.
To explore whether residual confounding arising from thisAIDS Research and Treatment 5
Table 2: Cox proportional (unadjusted and adjusted) hazard ratios for predictors of cart initiation.
Covariate
Univariate analysis Multivariate analysisb
Unadjusted hazard
ratio
95% conﬁdence
interval (CI) P value Adjusted hazard
ratio (AHR)
95%
Conﬁdence
interval (CI)
P value
Enrolled in the cap period 0.86 0.82, 0.90 <0.001 0.87 0.83, 0.92 <0.001
Use of Cotrimoxazole or Dapsonea 3.22 2.98, 3.48 <0.001 2.08 1.89, 2.29 <0.001
On TB treatmenta 0.77 0.73, 0.82 <0.001 0.60 0.56, 0.64 <0.001
Male gender 1.13 1.08, 1.19 <0.001 1.14 1.09, 1.21 <0.001
Age (per year increase)a 1.00 1.00, 1.00 0.100 1.00 1.00, 1.00 0.950
CD4 (per cell increase)a 0.995 0.994, 0.995 <0.001 0.995 0.995, 0.996 <0.001
WHO Stage Ia 1.00 1.00
WHO Stage IIa 1.16 1.07, 1.26 <0.001 1.08 1.00, 1.17 0.053
WHO Stage IIIa 0.89 0.83, 0.95 0.001 1.20 1.11, 1.29 <0.001
WHO Stage IVa 1.33 1.20, 1.46 <0.001 1.86 1.67, 2.07 <0.001
Urban Clinica 1.03 0.99, 1.09 0.162 1.06 1.01, 1.11 0.030
Travel time < 30min 1.00 1.00
Travel time 30–60min 1.02 0.96, 1.09 0.494 0.99 0.93, 1.06 0.749
Travel time 1-2hr 1.05 0.98, 1.12 0.151 0.99 0.92, 1.06 0.742
Travel time > 2hr 1.11 1.03, 1.20 0.008 1.05 0.97, 1.14 0.246
aAt Enrollment.
bAdjusted for all covariates.
explains the increases in mortality and loss to follow-up
among the cap group, a sub-analysis was conducted in which
we restricted the population to only those who received
Cotrimoxazole or Dapsone. Our ﬁndings were marginally
aﬀected as a result (Mortality HR: 1.20, 95% CI: 1.04–1.40;
LTFU HR: 1.18, 95% CI: 1.08–1.28).
4. Discussion
These data suggest that even a relatively brief restriction of
cART initiation among otherwise eligible patients indepen-
dently contributes to a higher risk of mortality and loss
to follow-up. This is in spite of triaging the sicker patients
(as measured by CD4 and WHO clinical stage) to receive
cART before the healthier ones. These ﬁndings underscore
the negative eﬀects that can be expected from even a short-
termdelayintheinitiationofcARTamongotherwiseeligible
patients. We believe that our study did not show an eﬀect of
increased morbidity while still showing increased mortality
and LTFU because patients who developed new AIDS-
deﬁning illnesses died or became lost to follow-up before
these illnesses could be diagnosed and/or documented in the
clinical encounter.
In addition to the poor clinical outcomes arising directly
from the delays, it can be expected that the long-term
clinical eﬀectiveness of cART once initiated may also be
adversely aﬀected by virtue of patients initiating treatment
at more advanced levels of immune suppression [20].
Furthermore, there are important implications of delayed
cART initiation on transmission of HIV and tuberculosis
[3]. Prevention of mother-to-child transmission [21], pos-
texposure prophylaxis, and most recently HPTN 052 [22]
have demonstrated the dramatic impact that combination
antiretroviral treatment can have on HIV transmission.
As such delayed cART initiation has multiple downstream
consequences both for the patient themselves and for their
partners, oﬀspring and community. Given these recent data
on treatment for prevention as well as data on the clinical
consequence of ART delay, it is imperative that global
community continues its commitment to providing cART in
resource constrained settings. These data illustrate the stark
consequences of failing to live up to these commitments and
will put clinicians on the front-lines back in the unenviable
positionenduredpriortotheglobalscale-upofantiretroviral
treatment delivery: having to choose who will live, and who
will not.
There are several strengths to this study. The ﬁrst is
that the USAID-AMPATH Partnership is a large clinical
population, covering much of western Kenya, in both urban
and rural settings. As a result, this sample provided ample
statistical power to answer our primary question and is
broadly generalizable to other sub-Saharan Africa settings.
Second, AMPATH services are free to patients, eliminating
confounding due to fee for service care structures. Last,
because there were no pharmacy stock-outs during the study
period (other than the one that caused the circumstances for
the comparison), our ﬁndings are not confounded by other
disruptions in the supply chain.
Limitations to this analysis include the potential ran-
dom misclassiﬁcation due to clinician error in recording.
Similarly, incomplete ascertainment of outcomes may have
particularly aﬀected the morbidity analysis. Third, this is a
retrospective study, with its inherent limitations including
reliance on accuracy of written record and incomplete data.6 AIDS Research and Treatment
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(a) Kaplan-Meier estimates of cumulative survival function of time
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from enrollment to loss to follow-up (LTFU). Log-rank P<0.001
Figure 1: Kaplan-Meier estimates of cumulative survival function of time to (a) new AIDS deﬁning event (ADE); (b) death; (c) loss to
follow-up.
Fourth, there may be prescription bias, in which providers
started cART on patients who did not meet the initiation
guidelines but whom they felt would beneﬁt from treatment
nevertheless. If this occurred, it will have biased the results
towards the null.
5. Conclusions
Given the certainty that more people will become eligible
as early start strategies are implemented and that early
start, itself, is a prevention strategy, this study highlights the
need for international funding organizations and national
governments to continue and expand their commitment to
HIV care and treatment. Treatment programs can make the
best use of resources through task-shifting [23–25] and other
innovative models, such as community ART group models
[26], to ensure the continuous provision of cART to those
in need in resource-limited settings. The stakes for patients
are high and these data demonstrate that even small delays
in treatment initiation among patients who are immune8 AIDS Research and Treatment
suppressed can be fatal. As the HIV pandemic begins to
stabilize in sub-Saharan Africa, and as the population and
economic beneﬁts of treating HIV infection begin to accrue
there as elsewhere [20, 27], these data remind us that
turningbacktheclockandrestrictingevensickpatientsfrom
accessing treatment is simply not a reasonable option.
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